The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Biosimilars: Past, Present and Future
Posted 01 April 2010 | By
Facing steep increases in healthcare costs, US legislators are making a concerted effort to find new ways to reduce them. One approach targets the high cost of biologics. Biologics are typically very expensive. While justifications for their price tags include the high cost of development and manufacture, higher risk of failure and limited markets, a key reason is lack of competition. Unlike drugs, there is no regulatory pathway for approval of generic versions of biologics in the US. Hence, a biologic can survive in the market for a longer time without fear of cheaper competitors.